中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | ethyl s-triazolo[3,4-b]benzothiazol-3-ylthioacetate | 40527-73-9 | C12H11N3O2S2 | 293.37 |
2H-苯并[4,5]噻唑并[2,3-c][1,2,4]噻唑-3-硫酮 | benzo[4,5]thiazolo[2,3- c][1,2,4]triazole-3-thiol | 6957-85-3 | C8H5N3S2 | 207.28 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | Methyl 2-[[2-([1,2,4]triazolo[3,4-b][1,3]benzothiazol-1-ylsulfanyl)acetyl]amino]acetate | 1181110-75-7 | C13H12N4O3S2 | 336.395 |
—— | Methyl 3-[[2-([1,2,4]triazolo[3,4-b][1,3]benzothiazol-1-ylsulfanyl)acetyl]amino]propanoate | 1423012-55-8 | C14H14N4O3S2 | 350.422 |
—— | s-triazolo[3,4-b]benzothiazol-3-ylthioacetyl (L)-serine methyl ester | 1423012-50-3 | C14H14N4O4S2 | 366.422 |
—— | s-triazolo[3,4-b]benzothiazol-3-ylthioacetyl (L)-valine methyl ester | 1423012-53-6 | C16H18N4O3S2 | 378.476 |
—— | s-triazolo[3,4-b]benzothiazole-3-thioacetyl (L)-methionine methyl ester | 1423012-41-2 | C16H18N4O3S3 | 410.542 |
—— | s-triazolo[3,4-b]benzothiazol-3-ylthioacetyl (L)-leucine methyl ester | 1423012-54-7 | C17H20N4O3S2 | 392.503 |
The search for novel antimicrobial agents effective against the emerging resistant pathogenic microorganisms to the currently used drugs is a substantial need. Herein, a novel series of compounds bearing a benzothiazolotriazole scaffold was synthesized and evaluated as potential antimicrobial agents against a panel of gram +ve, gram -ve bacteria, and fungi species.
The new compounds were synthesized via hybridization between the benzothiazolotriazole scaffold and thiadiazole ring or various substituted aromatic moieties using the tethering technique in drug discovery.
The in vitro results revealed that these compounds have significant antifungal activity rather than antibacterial potential due to their high similarity with tricyclazole. Compound 7b bearing bromo-phenyl moiety was the most potent derivative with an MIC value of 8 μg/mL against Candida albicans and Penicillium chrysogenum.
Collectively, benzothiazolotriazole-based derivatives are good antifungal leads and should be further actively pursued to expand treatment options for systemic and topical fungal infections.